Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IMMP
Immutep Limited
stock NASDAQ ADR

At Close
Sep 3, 2026 3:59:30 PM EDT
0.3604USD-5.876%(-0.0225)132,709
0.00Bid   0.00Ask   0.0000Spread
Pre-market
Sep 2, 2026 9:06:30 AM EDT
0.3620USD-5.458%(-0.0209)0
After-hours
Sep 3, 2026 4:13:30 PM EDT
0.3679USD+2.081%(+0.0075)2,001
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced today that Immutep CEO Marc Voigt has been invited to participate in the following investor conferences scheduled to take place in February 2022.   GlobeNewswire Inc
Jan 25, 2022
08:00AM EST  Immutep Quarterly Activities Report   GlobeNewswire Inc
Dec 16, 2021
08:32AM EST  Immutep Says Advances IMP761 Manufacturing   Benzinga
08:00AM EST  Immutep Advances IMP761 Manufacturing   GlobeNewswire Inc
Dec 15, 2021
04:23PM EST  Immutep Signs Agreement With Northway Biotech For Manufacturing IMP761 Ahead Of Clinical Testing   Benzinga
Dec 8, 2021
09:57AM EST  CORRECTION: Immutep Shares Have Not Been Halted In Wednesday's Session   Benzinga
Dec 2, 2021
08:07AM EST  Immutep Reports Good Safety From First Five Patients In Triple Combination Therapy Efti Study, Insight-003   Benzinga
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first five patients have been treated in the INSIGHT-003 study.   GlobeNewswire Inc
Dec 1, 2021
04:29PM EST  Immutep Reports On Safety From First 5 Patients In Triple Combo Therapy Study, INSIGHT-003   Benzinga
Nov 19, 2021
08:02AM EST  Immutep Reports Successfully Completed Recruitment For Phase 2 TACTI-002 Study Of LAG-3 Therapy   Benzinga
08:00AM EST  Immutep Successfully Completes Recruitment for Phase II TACTI-002   GlobeNewswire Inc
Nov 18, 2021
04:57PM EST  Immutep Says Successfully Completes Recruitment For Phase II TACTI-002 Study Of LAG-3 Therapy, Eftilagimod Alpha   Benzinga
Nov 15, 2021
11:04AM EST  Immutep Granted Chinese Patent For Eftilagimod Alpha, A Soluble Lag-3 Fusion Protein, In Combination With A PD-1 Pathway Inhibitor   Benzinga
08:00AM EST  Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at   GlobeNewswire Inc
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL 201680005401.3) entitled Combined Preparations for the Treatment of Cancer or Infection by the Chinese Patent Office.   GlobeNewswire Inc
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
Nov 9, 2021
11:44AM EST  Immutep Reports Improved And Statistically Significant Survival Benefit For Three Key Patient Groups In Final Phase IIb AIPAC Study Results In Metastatic Breast Cancer   Benzinga
08:05AM EST  Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003   GlobeNewswire Inc
08:00AM EST  Immutep Reports Improved and Statistically Significant Survival   GlobeNewswire Inc
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 2, 2021
10:41AM EDT  Immutep Announced Monday it was Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination With a Chemotherapy Agent   Benzinga
08:00AM EDT  Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble   GlobeNewswire Inc
Oct 29, 2021
08:00AM EDT  -- Positive feedback for the general clinical development program including the planned registrational Phase III trial in metastatic breast cancer (MBC) -- Other regulatory engagement ongoing, including with the US Food and Drug Administration (FDA)   GlobeNewswire Inc
06:24AM EDT  Immutep Filing Shows Co. Received European Medicines Agency Advice For Further Clinical Development Of Efti In Metastatic Breast Cancer, Including Phase 3 Trial   Benzinga
Oct 28, 2021
08:00AM EDT  Immutep Quarterly Activities Report & Appendix 4C   GlobeNewswire Inc
Oct 27, 2021
05:38PM EDT  Immutep Reports Q1 2022 Cash Receipts From Customers $56K   Benzinga
Oct 20, 2021
06:28AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.00 A.M. EDT).   RTTNews
Oct 1, 2021
08:05AM EDT  Immutep To Present Phase II TACTI-002 Data At SITC 2021   Benzinga
Sep 29, 2021
08:00AM EDT  Immutep Receives A$3.4 million R&D Tax Incentive from French   GlobeNewswire Inc
05:51AM EDT  Immutep Reported Late Tuesday that it Received A$3.4M R&D French Tax Incentive   Benzinga
Sep 28, 2021
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, will present at investor conferences, as outlined below.   GlobeNewswire Inc
Sep 21, 2021
08:38AM EDT  Immutep to Present Final Overall Survival Data   GlobeNewswire Inc
04:43AM EDT  Immutep to present final Overall Survival data from Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021   Benzinga
Sep 1, 2021
08:14AM EDT  Immutep Completes Recruitment Of Second Line PD-1/PD-L1 Refractory Non-Small Cell Lung Cancer Patients In TACTI-002   Benzinga
08:00AM EDT  Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory   GlobeNewswire Inc
Aug 31, 2021
08:08AM EDT  Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline; Terms Not Disclosed   Benzinga
08:00AM EDT  SYDNEY, AUSTRALIA 31 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) is pleased to advise its Chinese partner for eftilagimod alpha (efti or IMP321), EOC Pharma (EOC) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China.   GlobeNewswire Inc
Aug 27, 2021
08:02AM EDT  Immutep Announces Chinese Patent Grant For LAG-3 Antagonist Antibody LAG525   Benzinga
08:00AM EDT  SYDNEY, AUSTRALIA 27 August 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), is pleased to announce the grant of patent no. ZL201580013695.X entitled Antibody molecules to LAG-3 and uses thereof by the Chinese Patent Office.   GlobeNewswire Inc
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 5, 2021
05:11AM EDT  Immutep Announced Wednesday 1st Patient Dosed in INSIGHT-003 investigator-initiated Trial   Benzinga
Aug 3, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2021   Benzinga
09:38AM EDT  Ladenburg Thalmann Initiates Coverage On Immutep with Buy Rating, Announces Price Target of $8.3   Benzinga
Jul 13, 2021
08:03AM EDT  Immutep Provides Quarterly Activities Report   Benzinga
Jul 6, 2021
08:19AM EDT  Immutep Gets FDA And IRB Approval In The US For Phase IIb TACTI-003 Trial In Head And Neck Squamous Cell Carcinoma   RTTNews
08:02AM EDT  Immutep Says Receives FDA, IRB Approval In U.S. For Phase IIb TACI-003 Trial In HNSCC   Benzinga
08:00AM EDT  Immutep receives FDA and IRB approval in the US for Phase IIb   GlobeNewswire Inc
07:20AM EDT  Immutep Shares Are Trading Higher On Green Signal To Start Efti Combo Trial In First-Line Head & Neck Cancer   Benzinga
Jul 5, 2021
07:01PM EDT  Immutep Limited Announced FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC   Benzinga
Jun 21, 2021
09:17AM EDT  Immutep Limited (IMMP, IMM.AX) said Monday that it will commence a new phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha or "efti" or "IMP321" in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy.   RTTNews
08:13AM EDT  Immutep Signs Agreement To Commence New Phase I Trial, Called INSIGHT-003   RTTNews
08:06AM EDT  Immutep Reports Will Evaluate Efti In Triple Combo Therapy Phase 1 Study With Chemotherapy, Anti-PD-1 Therapy   Benzinga
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or Company), is pleased to announce that it has received commitments for a A$60 million two-tranche private placement of new ordinary shares (New Shares) to professional, institutional and sophisticated investors (Placement).   GlobeNewswire Inc
08:00AM EDT  -- New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours -- Expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapy -- First patient in expected in Q3 of calendar year 2021, with initial interim results expected in 2022   GlobeNewswire Inc
07:28AM EDT  Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement   Benzinga
Jun 20, 2021
08:26PM EDT  Immutep Announced it Secured Commitments for A$60M in a Placement   Benzinga
08:23PM EDT  Immutep Announced it Will Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy   Benzinga
Jun 9, 2021
06:45AM EDT  Immutep TACTI-002 And INSIGHT Clinical Results & Update Global Webcast Slides (Link)   Benzinga
Jun 8, 2021
08:16AM EDT  Immutep Provides Update On Its Preclinical Development Pipeline   RTTNews
08:04AM EDT  Immutep Reveals New Anti-LAG-3 Research Program   Benzinga
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline.   GlobeNewswire Inc
Jun 4, 2021
10:31AM EDT  Immutep Highlights Encouraging Data from Lead Oncology Candidate at ASCO 2021   Benzinga
08:03AM EDT  Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021   Benzinga
08:00AM EDT  Immutep Reports Positive Final Data from the INSIGHT-004 Phase I   GlobeNewswire Inc
08:00AM EDT  Immutep Reports Positive Data from its TACTI-002 Phase II Study of   GlobeNewswire Inc
Jun 2, 2021
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number EP3473263 entitled Combined Preparations for the Treatment of Cancer by the European Patent Office.   GlobeNewswire Inc
05:22AM EDT  Immutep Granted Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor   Benzinga
Jun 1, 2021
09:05AM EDT  Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors   Benzinga
08:32AM EDT  Australian biotechnology firm Immutep Ltd. (IMMP) announced Tuesday a new collaboration and supply agreement with German science and technology firm Merck KGaA (MKGAY.PK) for a Phase I/IIa clinical trial in patients with solid tumours, called INSIGHT-005.   RTTNews
08:17AM EDT  Immutep Announces New Collaboration And Supply Agreement With Merck KGaA   RTTNews
08:03AM EDT  Immutep Says Enters Into Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti   Benzinga
08:00AM EDT  -- Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfa -- New investigator-initiated explorative, multi-centre, open-labelled Phase I/IIa trial in 12 previously treated patients with different solid tumours, called INSIGHT-005 -- First patient is expected to be enrolled and dosed in H2 of calendar year 2021   GlobeNewswire Inc
05:09AM EDT  Immutep Announced New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti   Benzinga
May 26, 2021
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL201480073584.3) entitled Combined Preparations for the Treatment of Cancer by the Chinese Patent Office.   GlobeNewswire Inc
05:14AM EDT  Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination   Benzinga
May 25, 2021
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1st to 4th.   GlobeNewswire Inc
May 20, 2021
08:03AM EDT  Immutep Announces Publication Of TACTI-002 And INSIGHT-004 Abstracts For ASCO 2021 Annual Meeting   Benzinga
08:00AM EDT  Immutep Announces Publication of TACTI-002 and INSIGHT-004   GlobeNewswire Inc
May 7, 2021
08:00AM EDT  Immutep Operational Update   GlobeNewswire Inc
Apr 28, 2021
10:25AM EDT  Immutep Says To Announce New TACTI-002 And INSIGHT-004 Data In Poster Presentations and Discussion At ASCO 2021 Annual Meeting; Shares Move Higher   Benzinga
10:25AM EDT  Immutep To Announce New TACTI-002 and INSIGHT-004   GlobeNewswire Inc
Apr 19, 2021
08:00AM EDT  Immutep Quarterly Activities Report   GlobeNewswire Inc
Apr 16, 2021
08:00AM EDT  Immutep Receives A$1,155,055 R&D Tax Incentive   GlobeNewswire Inc
Apr 8, 2021
08:16AM EDT  Immutep Gets Fast Track Designation From FDA For Efti In First Line Recurrent/Metastatic Head & Neck Cancer   RTTNews
08:14AM EDT  The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data   Benzinga
08:00AM EDT  Immutep Achieves Fast Track Designation From US FDA For Efti, A   GlobeNewswire Inc
05:51AM EDT  Immutep Announced it Received Fast Track Designation From the FDA for Efti, a Soluble Lag-3 Protein, in First Line Recurrent/Metastatic Head & Neck Cancer   Benzinga
Apr 7, 2021
08:08AM EDT  Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy   Benzinga
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number EP3317301 entitled Combination therapies comprising antibody molecules to LAG-3 by the European Patent Office.   GlobeNewswire Inc
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
Apr 6, 2021
10:34AM EDT  Biotech Immunotherapy Company Immutep Sets the Standard with its LAG-3 Research   Benzinga
Mar 25, 2021
02:45PM EDT  Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference   Benzinga
10:21AM EDT  Immutep Limited (IMMP) shares are rising more than 53 percent on Thursday morning trade, continuing a surge since yesterday. There were no specific announcements from the company to influence the stock movement today.   RTTNews
10:12AM EDT  Mid-Morning Market Update: Markets Mostly Lower; Darden Restaurants Tops Q3 Views   Benzinga
Mar 23, 2021
07:12PM EDT  Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021   Benzinga
Mar 17, 2021
08:00AM EDT  Immutep To Participate In A Fireside Chat At The Inaugural M Vest   GlobeNewswire Inc
Mar 16, 2021
09:15AM EDT  Immutep's Lead Candidate To Be Tested In Combination With Keytruda In Second Head & Neck Cancer Study   Benzinga
08:07AM EDT  Immutep Announces Second Collaboration For New Phase IIb Trial To Evaluate Eftilagimod Alpha In Combination with KEYTRUDA   Benzinga
08:00AM EDT  -- New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSDs KEYTRUDA (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC) -- HNSCC is one of the more common cancers worldwide and has a high unmet medical need -- First patient is expected to be enrolled in mid-2021   GlobeNewswire Inc
Mar 9, 2021
09:17AM EST  Immutep Says Secures Second U.S. Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor   Benzinga
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number 10,940,181 entitled Combined Preparations for the Treatment of Cancer or Infection by the United States Patent & Trade Mark Office.   GlobeNewswire Inc
Mar 5, 2021
08:07AM EST  Immutep Confirms Yesterday Report Co Expanding Part B Of TACTI-002 Study   Benzinga
08:06AM EST  Immutep Says Expanding Part B Of TACTI-002 Study   Benzinga
08:00AM EST  Immutep Expands Part B of TACTI-002 Study   GlobeNewswire Inc
Mar 4, 2021
04:41PM EST  Immutep Expands Part B Of TACTI-002 Collaboration Trial   Benzinga
Feb 23, 2021
05:08AM EST  Immutep Reported Half Year Loss After Tax A$19.84M; Total Revenue and Other Income Down 78.6% to A$2.3M   Benzinga
Jan 27, 2021
08:02AM EST  Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In COVID-19 Patients To Randomized Portion Of The Study   Benzinga
08:00AM EST  -- Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID study -- Up to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic   GlobeNewswire Inc
07:36AM EST  The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement   Benzinga
05:29AM EST  Pre-market Movers In Healthcare Sector: TMBR, AEZS, SRNE,   RTTNews
Jan 26, 2021
05:30PM EST  Imutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In COVID-19 Patients   Benzinga
Jan 22, 2021
07:22AM EST  The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa   Benzinga
Jan 21, 2021
09:45PM EST  Immutep Limited (IMMP) said that its licensing partner GlaxoSmithKline plc. (GSK.L, GSK) has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, in patients with active ulcerative colitis.   RTTNews
06:03PM EST  Immutep Quarterly Activities Report   GlobeNewswire Inc
05:41PM EST  Ulcerative Colitis Phase II Study of GSK2831781 Discontinued   GlobeNewswire Inc
05:05PM EST  Immutep Reports Its Phase 2 Study For Ulcerative Colitis, GSK2831781, Discontinued   Benzinga
Jan 7, 2021
05:07AM EST  Immutep on Wednesday Reported Completion of Recruitment of Head and Neck Cancer Patients for Phase II TACTI-002 Study   Benzinga
Jan 6, 2021
07:05PM EST  -- Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) -- Recruitment of additional 1st line non small cell lung cancer (NSCLC) patients started -- Further interim data from TACTI-002 expected in H1 2021   GlobeNewswire Inc
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
04:56PM EST  Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor   Benzinga
04:54PM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled Combined Preparations for the Treatment of Cancer or Infection by the United States Patent & Trade Mark Office.   GlobeNewswire Inc
Dec 17, 2020
03:24PM EST  '$IMMP Immutep received a decision to grant European patent number EP3473263 titled "COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER"' - PatentGrants   Benzinga
Dec 16, 2020
08:08AM EST  Immutep Says Co Upscales Efti Manufacturing   Benzinga
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha (efti or IMP321).   GlobeNewswire Inc
05:25AM EST  Immutep- Says Prioritised Recommencement of Scaling Up Manufacturing of Lead Product Candidate Eftilagimod Alpha   Benzinga
Dec 15, 2020
08:04AM EST  Immutep Offers Update On 6 Clinical Trials; Says Has Cash Runway Beyond End Of 2022   Benzinga
08:01AM EST  -- Efti clinical trial status updates -- Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022   GlobeNewswire Inc
Dec 14, 2020
09:37AM EST  Learning Caution In A Volatile December   Benzinga
Dec 11, 2020
10:19AM EST  Mid-Morning Market Update: Markets Edge Lower; Pfizer Coronavirus Vaccine Receives FDA Panel's Nod   Benzinga
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
02:35PM EST  Mid-Afternoon Market Update: Dow Falls Over 100 Points; Airbnb Shares Spike Higher   Benzinga
02:31PM EST  Mid-Afternoon Market Update: Dow Falls Over 100 Points; Neos Therapeutics Shares Spike Higher   Benzinga
12:21PM EST  Mid-Day Market Update: Crude Oil Surges 4%; AquaBounty Technologies Shares Plummet   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Mixed; Adobe Earnings Top Views   Benzinga
10:08AM EST  Shares of Australia-based biotechnology company Immutep Limited (IMMP) are surging almost 257 percent or $5.52 in Thursday's morning trade at $7.67, after hitting a new 52-week high of $7.95.   RTTNews
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 9, 2020
05:53PM EST  Immuteps Chinese Partner EOC Pharma to Start   GlobeNewswire Inc
05:14PM EST  Immutep Reports Statistically Significant Survival Benefit for Key   GlobeNewswire Inc
04:36PM EST  Immutep Shares Spike Higher; Traders Circulate Report Titled 'ImmutepReportsStatistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Studyin Metastatic Breast Cancer'   Benzinga
Nov 19, 2020
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
Nov 18, 2020
06:19PM EST  Immutep Announces Expansion of TACTI-002 Collaboration Trial   GlobeNewswire Inc
05:59PM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (Immutep or the Company), which is listed on NASDAQ and the Australian Securities Exchange, is pleased to announce that it has today successfully completed a A$29.6 million a private placement of ordinary shares to professional and institutional investors (Placement).   GlobeNewswire Inc
Nov 11, 2020
11:47AM EST  UPDATE: Maxim Raised Price Target On Immutep Follows Sentiment 'The Data for Efti in Lung and Head And Neck Continues to Build'   Benzinga
Nov 9, 2020
03:45PM EST  Immutep Shares Spike To Session High; Traders Circulate Purported Company Press Release Showing Favorable Response Rates In Phase II TACTI-002 Study Of IMP321 And Keytruda For Cancer   Benzinga
08:18AM EST  Immutep Announces Australian Patent Grant For IMP701 Antibody   Benzinga
08:00AM EST  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no. 2015229103 entitled Antibody molecules to LAG-3 and uses thereof by the Australian Patent Office.   GlobeNewswire Inc
Nov 2, 2020
05:24PM EST  Immuteps TACTI-002 Data to Be Presented at   GlobeNewswire Inc
Oct 29, 2020
08:55AM EDT  Immutep Reports Collaboration With LabCorp To Develop Oncology Services, Products, No Terms Disclosed   Benzinga
Oct 23, 2020
08:10AM EDT  Immutep Announces Start Of An Investigator-Initiated Phase II Study In Coronavirus Patients   Benzinga
08:00AM EDT  Immutep Announces the Start of an Investigator-Initiated Phase II   GlobeNewswire Inc
Oct 21, 2020
10:44AM EDT  Why Immutep's Stock Is Trading Higher Today   Benzinga
08:22AM EDT  Immutep Granted European Patent For IMP761   Benzinga
08:19AM EDT  Immutep Announces Grant Of European Patent For IMP761   RTTNews
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled Anti-LAG-3 Antibodies by the European Patent Office.   GlobeNewswire Inc
Oct 19, 2020
08:00AM EDT  Immutep to Present AIPAC Overall Survival Data at the San Antonio   GlobeNewswire Inc
Sep 18, 2020
05:46AM EDT  Immutep Last Night Announced Improving Results from INSIGHT-004 Trial   Benzinga
Sep 17, 2020
08:48PM EDT  Immutep Announces Improving Results From Stage I Of Phase II TACTI-002 Study   RTTNews
08:24PM EDT  Immutep Announces Improving Results from Stage I of Phase II   GlobeNewswire Inc
07:53PM EDT  -- 41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%) -- Encouraging early anti-tumour activity signals in a variety of cancer indications not typically sensitive to immune checkpoint inhibitor (ICI) therapy -- Combination of eftilagimod alpha and avelumab continues to be safe and well tolerated   GlobeNewswire Inc
Aug 31, 2020
08:15AM EDT  Immutep, Monash University Receive A$671,427 In Grant Funding For LAG-3 Project   Benzinga
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,427 grant under the ARCs Linkage Project scheme to support their research collaboration into Lymphocyte Activation Gene-3 (LAG-3) for a further three years.   GlobeNewswire Inc
Aug 26, 2020
08:00AM EDT  New Data From Immuteps efti to be Presented at ESMO   GlobeNewswire Inc
Aug 18, 2020
08:00AM EDT  -- 23 patients with second line Non-Small Cell Lung Cancer (NSCLC) participating in Stage 1, Part B -- Total of 87 patients out of up to 109 patients (80%) are enrolled and participating in the trial, with recruitment continuing for stage 2 of Part C at present -- Further data from TACTI-002 expected throughout calendar year 2020   GlobeNewswire Inc
Aug 17, 2020
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP)("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, issued a newsletter to update its shareholders from Executive Director and Chief Executive Officer Marc Voigt, which is available below, and a formatted version is available on the Companys website (click here).   GlobeNewswire Inc
Aug 11, 2020
08:16AM EDT  Immutep Granted U.S. Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination   Benzinga
08:00AM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 10,736,940) entitled Combined Preparations for the Treatment of Cancer by the United States Patent Office.   GlobeNewswire Inc
06:10AM EDT  Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-immunotherapy Combination   Benzinga
Jul 15, 2020
12:12PM EDT  Mid-Day Market Update: Nasdaq Turns Negative; Immutep Shares Spike Higher   Benzinga
Jul 14, 2020
07:03PM EDT  Immutep Announces United States Patent Grant for IMP701 Antibody   Benzinga
07:00PM EDT  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company) announces the grant of patent no. 10,711,060 entitled Antibody molecules to LAG-3 and uses thereof by the United States Patent and Trade Mark Office.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC